CDKN2A and hepatocellular carcinoma: Several mechanisms that lead to p16 inactivation have been described, including point mutations, homozygous deletions, and promoter hypermethylation [7][8][9], and hypermethylation of the p16 gene promoter has been shown to occur more frequently in HCC patients [10][11][12].